Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Ambea on a rights issue
Mandate

Vinge has advised Ambea on a rights issue

June 19, 2019 Capital Markets and Public M&A

Vinge has advised Ambea AB (publ) on a fully subscribed rights issue, which will provide Ambea with issue proceeds amounting to approximately SEK 1,215 million before costs.

The new shares are expected to be admitted to trading on Nasdaq Stockholm on 25 June 2019.

Ambea is the market leading private care provider in Sweden, Norway and Denmark respectively, with about 900 units and around 26,000 employees. Through the brands Nytida, Vardaga, Lära, Klara, Stendi and Altiden, Ambea provides housing, support, education and personnel for health and social care.

Ambea is listed on Nasdaq Stockholm, Mid cap.

Vinge’s team consisted primarily of Charlotte Levin, Nils Fredrik Dehlin, Annika Nyberg Ekenberg and Marcus Gustavsson.
 

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

 SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026